Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Patients with relapsed or refractory indolent (low-grade) NHL~* Who have received 1-3 prior treatments with chemotherapy~Exclusion criteria~* Patients previously treated with fludarabine~* Prior treatment with rituximab (Rituxan), unless there was a complete response (CR) or partial response (PR) to that treatment~* Patients known to have an allergic reaction to rituximab, or to murine proteins.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).